Carlos L. Arteaga, M.D.

Professor

carlos.arteaga@vanderbilt.edu
Faculty Appointments
Professor of Medicine Donna S. Hall Chair in Breast CancerProfessor of Cancer BiologyProfessor of Cancer Biology
Education
M.D., Medicine, Universidad Catolica de Guayaquil, Guayaquil, Ecuador
Office Address
2220 Piece Avenue
777 Preston Research Bldg.
TN 37232-6307
Research Description
Carlos L. Arteaga obtained his M.D. degree with honors in 1980 at the Facultad the Ciencias M¿¿dicas of the University of Guayaquil in Guayaquil, Ecuador. He trained in Internal Medicine and Medical Oncology at Emory University (Atlanta, GA) and the University of Texas Health Sciences Center in San Antonio, TX, respectively. He joined Vanderbilt in 1989 where he now holds the Donna S. Hall Chair in Breast Cancer Research and serves as Professor of Medicine and Cancer Biology. Dr. Arteaga is also Associate Director for Translational/Clinical Research at the Vanderbilt-Ingram Cancer Center (VICC) where he leads the Breast Cancer Program and the recently founded Center for Cancer Targeted Therapies. He has over 250 publications in the areas of signaling by growth factor receptors and oncogenes in breast tumor cells, development of targeted therapies and biomarkers of drug action or resistance in breast cancer, and investigator-initiated clinical trials. His work includes the first demonstration that blockade of IGF-I receptor results in an antitumor effect in breast cancer; the first observation that tumor-host TGF¿¿¿-mediated interactions are critical for breast tumor establishment and metastatic progression, thus providing a basis for the targeting of TGF¿¿¿ in cancers with a therapeutic intent; one of the first observations that loss of tumor suppressor PTEN confers resistance to ERBB receptor-targeted therapies; the role of p27 haploinsufficiency in breast cancer progression; and the role of PI3K signaling on resistance to antiestrogens in breast cancer.

Since 2002, he has directed the NCI-funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE) where he co-leads several investigator-initiated clinical trials. He is funded by the National Cancer Institute, the American Cancer Society, the Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C) and the Susan G. Komen for the Cure and Breast Cancer Research Foundations. He is a member of the American Society of Clinical Investigation (1998) and the Association of American Physicians (2005). He served as member of the Experimental Therapeutics-2 NIH Study Section (1998-2003), the NCI Board of Scientific Counselors (1999-2004), NCI Parent Subcommittee A for review of Cancer Centers (2004-2008), the Breast Core Committee of the Eastern Cooperative Oncology Group (ECOG), and the Board of Directors of the American Association for Cancer Research (2004-2007). He co-chaired the former Developmental Therapeutics Committee of ECOG and chaired the AACR Special Conferences Committee (2002-2008). Arteaga is the recipient of the 2003 AACR Richard & Hinda Rosenthal Award, the 2007-2017 ACS Clinical Research Professor Award, the 2009 Gianni Bonadonna Award from the American Society of Clinical Oncology (ASCO) and the 2011 Brinker Award for Scientific Distinction from the Susan G. Komen for the Cure Foundation. As of this year, he serves in the Scientific Advisory Board of the Susan G. Komen for tehe Cure Breast Cancer Foundation. He co-chaired the AACR Special Conference ¿¿¿Advances in Breast Cancer Research¿¿¿ in 2003, 2005, 2007, 2009 and 2013. He has served as AACR co-chair of the annual San Antonio Breast Cancer Symposium since 2009. He is Deputy Editor of Clinical Cancer Research and member of the Editorial Board of Cancer Cell and six other peer-reviewed journals. He serves on the advisory boards of several NCI Breast Cancer Research Programs and NCI-designated Cancer Centers. In 2013, he was elected as President Elect of the American Association for Cancer Research.
Research Keywords
Oncogene signaling in breast development/transformation and breast cancer progression Mechanisms of resistance to targeted therapies in breast cancer Novel clinical trials in breast cancer
Clinical Research Keywords
breast cancer, molecular therapeutics, tyrosine kinase inhibitors
Publications
Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene [print-electronic]. 2015 Jul 7/23/2015; 34(30): 3968-76. PMID: 25284585, PMCID: PMC4387124, PII: onc2014328, DOI: 10.1038/onc.2014.328, ISSN: 1476-5594.

Abramson RG, McGhee CR, Lakomkin N, Arteaga CL. Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics. Acad Radiol [print-electronic]. 2015 Jun; 22(6): 779-86. PMID: 25794800, PMCID: PMC4429002, PII: S1076-6332(15)00051-3, DOI: 10.1016/j.acra.2015.01.015, ISSN: 1878-4046.

Ju JH, Oh S, Lee KM, Yang W, Nam KS, Moon HG, Noh DY, Kim CG, Park G, Park JB, Lee T, Arteaga CL, Shin I. Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes. Cell Death Differ [print-electronic]. 2015 Apr; 22(4): 665-76. PMID: 25342465, PMCID: PMC4356337, PII: cdd2014155, DOI: 10.1038/cdd.2014.155, ISSN: 1476-5403.

Walsh AJ, Cook RS, Lee JH, Arteaga CL, Skala MC. Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts. J Biomed Opt. 2015 Feb; 20(2): 26004. PMID: 25700233, PMCID: PMC4335617, PII: 2173302, DOI: 10.1117/1.JBO.20.2.026004, ISSN: 1560-2281.

Whisenant JG, McIntyre JO, Peterson TE, Kang H, Sánchez V, Manning HC, Arteaga CL, Yankeelov TE. Utility of [18¿F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts. Mol Imaging Biol. 2015 Feb; 17(1): 119-28. PMID: 25034624, PMCID: PMC4311727, DOI: 10.1007/s11307-014-0770-z, ISSN: 1860-2002.

Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res [print-electronic]. 2015 Jan 1/15/2015; 75(2): 405-14. PMID: 25480943, PMCID: PMC4297507, PII: 0008-5472.CAN-14-2475, DOI: 10.1158/0008-5472.CAN-14-2475, ISSN: 1538-7445.

Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, Gomez HL. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematol Oncol Stem Cell Ther [print-electronic]. 2014 Dec; 7(4): 142-8. PMID: 25467032, PII: S1658-3876(14)00084-3, DOI: 10.1016/j.hemonc.2014.09.007, ISSN: 1658-3876.

Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 2014 Oct 10/15/2014; 5(19): 9049-64. PMID: 24979294, PMCID: PMC4253418, PII: 2022, DOI: 10.18632/oncotarget.2022, ISSN: 1949-2553.

Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MC. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res [print-electronic]. 2014 Sep 9/15/2014; 74(18): 5184-94. PMID: 25100563, PMCID: PMC4167558, PII: 0008-5472.CAN-14-0663, DOI: 10.1158/0008-5472.CAN-14-0663, ISSN: 1538-7445.

McCormack DR, Walsh AJ, Sit W, Arteaga CL, Chen J, Cook RS, Skala MC. In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts. Biomed Opt Express. 2014 Jul 7/1/2014; 5(7): 2247-61. PMID: 25071962, PMCID: PMC4102362, PII: 210394, DOI: 10.1364/BOE.5.002247, ISSN: 2156-7085.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.

Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res. Treat [print-electronic]. 2014 Jun; 145(2): 389-99. PMID: 24722917, PMCID: PMC4046906, DOI: 10.1007/s10549-014-2945-3, ISSN: 1573-7217.

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol [print-electronic]. 2014 Apr 4/20/2014; 32(12): 1202-9. PMID: 24663045, PMCID: PMC3986383, PII: JCO.2013.54.0518, DOI: 10.1200/JCO.2013.54.0518, ISSN: 1527-7755.

Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA. Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res [print-electronic]. 2014 Apr 4/1/2014; 20(7): 1757-67. PMID: 24398047, PMCID: PMC3998833, PII: 1078-0432.CCR-13-2332, DOI: 10.1158/1078-0432.CCR-13-2332, ISSN: 1078-0432.

Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014 Mar 3/17/2014; 25(3): 282-303. PMID: 24651011, PMCID: PMC4018830, PII: S1535-6108(14)00086-5, DOI: 10.1016/j.ccr.2014.02.025, ISSN: 1878-3686.

Bi X, Rexer B, Arteaga CL, Guo M, Mahadevan-Jansen A. Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy. J Biomed Opt. 2014 Feb; 19(2): 25001. PMID: 24496495, PMCID: PMC3913568, PII: 1828548, DOI: 10.1117/1.JBO.19.2.025001, ISSN: 1560-2281.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov [print-electronic]. 2014 Feb; 4(2): 232-45. PMID: 24356096, PMCID: PMC3946308, PII: 2159-8290.CD-13-0286, DOI: 10.1158/2159-8290.CD-13-0286, ISSN: 2159-8290.

Arteaga CL. Progress in breast cancer: overview. Clin. Cancer Res. 2013 Dec 12/1/2013; 19(23): 6353-9. PMID: 24298065, PII: 19/23/6353, DOI: 10.1158/1078-0432.CCR-13-2549, ISSN: 1078-0432.

Hanker AB, Cook RS, Arteaga CL. Mouse models and anti-HER2 therapies. Oncotarget. 2013 Nov; 4(11) Sect. 1866,7.

Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC. Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Cancer Res. 2013 Oct 10/15/2013; 73(20): 6164-74. PMID: 24130112, PMCID: PMC3801432, PII: 73/20/6164, DOI: 10.1158/0008-5472.CAN-13-0527, ISSN: 1538-7445.

Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Res [print-electronic]. 2013 Jul 7/1/2013; 73(13): 4075-85. PMID: 23633485, PMCID: PMC3702683, PII: 0008-5472.CAN-12-4579, DOI: 10.1158/0008-5472.CAN-12-4579, ISSN: 1538-7445.

Rexer BN, Shyr Y, Arteaga CL. Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy [editorial]. J. Clin. Oncol [print-electronic]. 2013 Jun 6/10/2013; 31(17): 2073-5. PMID: 23650407, PII: JCO.2012.48.5243, DOI: 10.1200/JCO.2012.48.5243, ISSN: 1527-7755.

Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-ß inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest [print-electronic]. 2013 Mar; 123(3): 1348-58. PMID: 23391723, PMCID: PMC3582135, PII: 65416, DOI: 10.1172/JCI65416, ISSN: 1558-8238.

Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin. Cancer Res [print-electronic]. 2013 Feb 2/1/2013; 19(3): 610-9. PMID: 23224399, PMCID: PMC3563762, PII: 1078-0432.CCR-12-2024, DOI: 10.1158/1078-0432.CCR-12-2024, ISSN: 1078-0432.

Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CL. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res [print-electronic]. 2013 Feb 2/1/2013; 73(3): 1190-200. PMID: 23204226, PMCID: PMC3563941, PII: 0008-5472.CAN-12-2440, DOI: 10.1158/0008-5472.CAN-12-2440, ISSN: 1538-7445.

Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Mol. Cancer Ther [print-electronic]. 2012 Oct; 11(10): 2301-5. PMID: 22879364, PMCID: PMC3682668, PII: 1535-7163.MCT-12-0511, DOI: 10.1158/1535-7163.MCT-12-0511, ISSN: 1538-8514.

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 2012 Jul; 18(7): 1052-9. PMID: 22683778, PMCID: PMC3693569, PII: nm.2795, DOI: 10.1038/nm.2795, ISSN: 1546-170X.

Sprung RW, Martinez MA, Carpenter KL, Ham AJ, Washington MK, Arteaga CL, Sanders ME, Liebler DC. Precision of multiple reaction monitoring mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue. J. Proteome Res [print-electronic]. 2012 Jun 6/1/2012; 11(6): 3498-505. PMID: 22530795, PMCID: PMC3368395, DOI: 10.1021/pr300130t, ISSN: 1535-3907.

Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL, Cook RS. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res [print-electronic]. 2012 May 5/15/2012; 72(10): 2672-82. PMID: 22461506, PMCID: PMC3693553, PII: 0008-5472.CAN-11-3594, DOI: 10.1158/0008-5472.CAN-11-3594, ISSN: 1538-7445.

Balko JM, Arteaga CL. Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms. Mol Diagn Ther. 2012 Feb 2/1/2012; 16(1): 1-6. PMID: 22339590, DOI: 10.2165/11597430-000000000-00000, ISSN: 1179-2000.

Arteaga CL, Baselga J. Impact of genomics on personalized cancer medicine. Clin. Cancer Res. 2012 Feb 2/1/2012; 18(3): 612-8. PMID: 22298893, PII: 18/3/612, DOI: 10.1158/1078-0432.CCR-11-2019, ISSN: 1078-0432.

Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2012 Jan 1/3/2012; 109(1): 221-6. PMID: 22178756, PMCID: PMC3252958, PII: 1115802109, DOI: 10.1073/pnas.1115802109, ISSN: 1091-6490.

Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012; 17(1): 1-16. PMID: 22471661, PMCID: PMC3394454, PII: 07ff3a573b26d6e9,237a039b425a836d, ISSN: 0893-9675.

Walsh A, Cook RS, Rexer B, Arteaga CL, Skala MC. Optical imaging of metabolism in HER2 overexpressing breast cancer cells. Biomed Opt Express [print-electronic]. 2012 Jan 1/1/2012; 3(1): 75-85. PMID: 22254170, PMCID: PMC3255344, PII: 156540, DOI: 10.1364/BOE.3.000075, ISSN: 2156-7085.

Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012 Jan; 9(1): 16-32. PMID: 22124364, PII: nrclinonc.2011.177, DOI: 10.1038/nrclinonc.2011.177, ISSN: 1759-4782.

Fox EM, Arteaga CL, Miller TW. Abrogating endocrine resistance by targeting ERa and PI3K in breast cancer. Front Oncol. 2012; 2: 145. PMID: 23087906, PMCID: PMC3472546, DOI: 10.3389/fonc.2012.00145, ISSN: 2234-943X.

Garrett JT, Chakrabarty A, Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer?. Oncotarget. 2011 Dec; 2(12): 1314-21. PMID: 22248929, PMCID: PMC3282088, PII: 409, DOI: 10.18632/oncotarget.409, ISSN: 1949-2553.

Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J. Clin. Oncol [print-electronic]. 2011 Nov 11/20/2011; 29(33): 4452-61. PMID: 22010023, PMCID: PMC3221526, PII: JCO.2010.34.4879, DOI: 10.1200/JCO.2010.34.4879, ISSN: 1527-7755.

Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res [print-electronic]. 2011 Nov 11/1/2011; 71(21): 6773-84. PMID: 21908557, PMCID: PMC3206206, PII: 0008-5472.CAN-11-1295, DOI: 10.1158/0008-5472.CAN-11-1295, ISSN: 1538-7445.

Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, González-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, Arteaga CL. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene [print-electronic]. 2011 Oct 10/6/2011; 30(40): 4163-74. PMID: 21499296, PMCID: PMC3204390, PII: onc2011130, DOI: 10.1038/onc.2011.130, ISSN: 1476-5594.

Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL. ERa-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov [print-electronic]. 2011 Sep; 1(4): 338-51. PMID: 22049316, PMCID: PMC3204388, PII: 2159-8290.CD-11-0101, DOI: 10.1158/2159-8290.CD-11-0101, ISSN: 2159-8290.

Arteaga CL. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?. Clin. Cancer Res [print-electronic]. 2011 Aug 8/1/2011; 17(15): 4919-21. PMID: 21670086, PMCID: PMC3221729, PII: 1078-0432.CCR-11-1218, DOI: 10.1158/1078-0432.CCR-11-1218, ISSN: 1078-0432.

Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, Horak ID, Arteaga CL. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res [print-electronic]. 2011 Jun 6/1/2011; 71(11): 3941-51. PMID: 21482676, PMCID: PMC3204389, PII: 0008-5472.CAN-10-3775, DOI: 10.1158/0008-5472.CAN-10-3775, ISSN: 1538-7445.

Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2011 Mar 3/22/2011; 108(12): 5021-6. PMID: 21385943, PMCID: PMC3064360, PII: 1016140108, DOI: 10.1073/pnas.1016140108, ISSN: 1091-6490.

Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res [print-electronic]. 2011; 13(6): 224. PMID: 22114931, PMCID: PMC3315683, PII: bcr3039, DOI: 10.1186/bcr3039, ISSN: 1465-542X.

Arteaga CL. ERBB receptors in cancer: signaling from the inside. Breast Cancer Res. 2011; 13(2): 304. PMID: 21457523, PMCID: PMC3219176, PII: bcr2829, DOI: 10.1186/bcr2829, ISSN: 1465-542X.

Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol. Cell. Biol [print-electronic]. 2008 Sep; 28(18): 5605-20. PMID: 18625725, PMCID: PMC2546920, PII: MCB.00787-08, DOI: 10.1128/MCB.00787-08, ISSN: 1098-5549.

Belkhiri A, Dar AA, Peng DF, Razvi MH, Rinehart C, Arteaga CL, El-Rifai W. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin. Cancer Res [print-electronic]. 2008 Jul 7/15/2008; 14(14): 4564-71. PMID: 18579663, PMCID: PMC2842884, PII: 1078-0432.CCR-08-0121, DOI: 10.1158/1078-0432.CCR-08-0121, ISSN: 1078-0432.

Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 2008 Jul; 118(7): 2609-19. PMID: 18568074, PMCID: PMC2430495, DOI: 10.1172/JCI34588, ISSN: 0021-9738.

Sanders ME, Dias EC, Xu BJ, Mobley JA, Billheimer D, Roder H, Grigorieva J, Dowsett M, Arteaga CL, Caprioli RM. Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. J. Proteome Res [print-electronic]. 2008 Apr; 7(4): 1500-7. PMID: 18386930, PMCID: PMC2738605, DOI: 10.1021/pr7008109, ISSN: 1535-3893.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J. Clin. Oncol [print-electronic]. 2008 Feb 2/20/2008; 26(6): 897-906. PMID: 18180460, PII: JCO.2007.13.5939, DOI: 10.1200/JCO.2007.13.5939, ISSN: 1527-7755.

Yang S, Park K, Turkson J, Arteaga CL. Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. Exp. Cell Res [print-electronic]. 2008 Jan 1/15/2008; 314(2): 413-9. PMID: 17927978, PMCID: PMC3221731, PII: S0014-4827(07)00426-0, DOI: 10.1016/j.yexcr.2007.09.002, ISSN: 0014-4827.

Criswell TL, Arteaga CL. Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility. J. Biol. Chem [print-electronic]. 2007 Nov 11/2/2007; 282(44): 32491-500. PMID: 17823118, PII: M704434200, DOI: 10.1074/jbc.M704434200, ISSN: 0021-9258.

Yang L, Amann JM, Kikuchi T, Porta R, Guix M, Gonzalez A, Park KH, Billheimer D, Arteaga CL, Tai HH, DuBois R, Carbone DP, Johnson DH. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res. 2007 Jun 6/15/2007; 67(12): 5587-93. PMID: 17575121, PII: 67/12/5587, DOI: 10.1158/0008-5472.CAN-06-2287, ISSN: 0008-5472.

Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest [print-electronic]. 2007 May; 117(5): 1305-13. PMID: 17415413, PMCID: PMC1838926, DOI: 10.1172/JCI30740, ISSN: 0021-9738.

Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol. Ther. 2007 Apr; 6(4): 561-70. PMID: 17495520, PMCID: PMC3395216, PII: 3851, ISSN: 1538-4047.

Wang SE, Narasanna A, Whitell CW, Wu FY, Friedman DB, Arteaga CL. Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J. Biol. Chem [print-electronic]. 2007 Feb 2/23/2007; 282(8): 5661-9. PMID: 17204482, PMCID: PMC4015524, PII: M608499200, DOI: 10.1074/jbc.M608499200, ISSN: 0021-9258.

Hinow P, Wang SE, Arteaga CL, Webb GF. Relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor. Theor Biol Med Model. 2007; 4: 14. PMID: 17407594, PMCID: PMC1852549, PII: 1742-4682-4-14, DOI: 10.1186/1742-4682-4-14, ISSN: 1742-4682.

Friedman DB, Wang SE, Whitwell CW, Caprioli RM, Arteaga CL. Multivariable difference gel electrophoresis and mass spectrometry: a case study on transforming growth factor-beta and ERBB2 signaling. Mol. Cell Proteomics [print-electronic]. 2007 Jan; 6(1): 150-69. PMID: 17028091, PII: D600001-MCP200, DOI: 10.1074/mcp.D600001-MCP200, ISSN: 1535-9476.

Perez-Torres M, Guix M, Gonzalez A, Arteaga CL. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J. Biol. Chem [print-electronic]. 2006 Dec 12/29/2006; 281(52): 40183-92. PMID: 17082181, PII: M607958200, DOI: 10.1074/jbc.M607958200, ISSN: 0021-9258.

Shin I, Arteaga CL. Expression of active Akt protects against tamoxifen-induced apoptosis in MCF-7 Cells. IUBMB Life. 2006 Nov; 58(11): 664-9. PMID: 17085387, PII: G41066566U772185, DOI: 10.1080/15216540601001681, ISSN: 1521-6543.

Qu S, Rinehart C, Wu HH, Wang SE, Carter B, Xin H, Kotlikoff M, Arteaga CL. Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy. Genesis. 2006 Oct; 44(10): 477-86. PMID: 16991114, DOI: 10.1002/dvg.20243, ISSN: 1526-954X.

Cornett DS, Mobley JA, Dias EC, Andersson M, Arteaga CL, Sanders ME, Caprioli RM. A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol. Cell Proteomics [print-electronic]. 2006 Oct; 5(10): 1975-83. PMID: 16849436, PII: M600119-MCP200, DOI: 10.1074/mcp.M600119-MCP200, ISSN: 1535-9476.

Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Res. 2006 Oct 10/1/2006; 66(19): 9591-600. PMID: 17018616, PII: 66/19/9591, DOI: 10.1158/0008-5472.CAN-06-2071, ISSN: 1538-7445.

Biswas S, Criswell TL, Wang SE, Arteaga CL. Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clin. Cancer Res. 2006 Jul 7/15/2006; 12(14 Pt 1): 4142-6. PMID: 16857784, PII: 12/14/4142, DOI: 10.1158/1078-0432.CCR-06-0952, ISSN: 1078-0432.

Yang S, Qu S, Perez-Tores M, Sawai A, Rosen N, Solit DB, Arteaga CL. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res. 2006 Jul 7/15/2006; 66(14): 6990-7. PMID: 16849543, PII: 66/14/6990, DOI: 10.1158/0008-5472.CAN-06-1042, ISSN: 0008-5472.

Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006 Jul; 10(1): 25-38. PMID: 16843263, PII: S1535-6108(06)00179-6, DOI: 10.1016/j.ccr.2006.05.023, ISSN: 1535-6108.

Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL. Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene [print-electronic]. 2006 Jun 6/8/2006; 25(24): 3408-23. PMID: 16186809, PII: 1208964, DOI: 10.1038/sj.onc.1208964, ISSN: 0950-9232.

Arteaga CL. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell. 2006 Jun; 9(6): 421-3. PMID: 16766261, PII: S1535-6108(06)00151-6, DOI: 10.1016/j.ccr.2006.05.014, ISSN: 1535-6108.

Wu FY, Wang SE, Sanders ME, Shin I, Rojo F, Baselga J, Arteaga CL. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res. 2006 Feb 2/15/2006; 66(4): 2162-72. PMID: 16489017, PII: 66/4/2162, DOI: 10.1158/0008-5472.CAN-05-3304, ISSN: 0008-5472.

Shin I, Miller T, Arteaga CL. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin. Cancer Res. 2006 Feb 2/1/2006; 12(3 Pt 2): 1008s-1012s. PMID: 16467117, PII: 12/3/1008s, DOI: 10.1158/1078-0432.CCR-05-2352, ISSN: 1078-0432.

Arteaga CL. Inhibition of TGFbeta signaling in cancer therapy. Curr. Opin. Genet. Dev [print-electronic]. 2006 Feb; 16(1): 30-7. PMID: 16377175, PII: S0959-437X(05)00220-0, DOI: 10.1016/j.gde.2005.12.009, ISSN: 0959-437X.

Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene. 2005 Jul 7/28/2005; 24(32): 5053-68. PMID: 15856015, PMCID: PMC3074577, PII: 1208685, DOI: 10.1038/sj.onc.1208685, ISSN: 0950-9232.

Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. Mol. Cell. Biol. 2005 Jun; 25(11): 4703-15. PMID: 15899872, PMCID: PMC1140650, PII: 25/11/4703, DOI: 10.1128/MCB.25.11.4703-4715.2005, ISSN: 0270-7306.

Shin I, Edl J, Biswas S, Lin PC, Mernaugh R, Arteaga CL. Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res. 2005 Apr 4/1/2005; 65(7): 2815-24. PMID: 15805282, PII: 65/7/2815, DOI: 10.1158/0008-5472.CAN-04-2898, ISSN: 0008-5472.

Yi JY, Shin I, Arteaga CL. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J. Biol. Chem [print-electronic]. 2005 Mar 3/18/2005; 280(11): 10870-6. PMID: 15657037, PII: M413223200, DOI: 10.1074/jbc.M413223200, ISSN: 0021-9258.

Shin I, Rotty J, Wu FY, Arteaga CL. Phosphorylation of p27Kip1 at Thr-157 interferes with its association with importin alpha during G1 and prevents nuclear re-entry. J. Biol. Chem [print-electronic]. 2005 Feb 2/18/2005; 280(7): 6055-63. PMID: 15579463, PII: M412367200, DOI: 10.1074/jbc.M412367200, ISSN: 0021-9258.

Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin. Cancer Res. 2005 Jan 1/15/2005; 11(2 Pt 2): 937s-43s. PMID: 15701890, PII: 11/2/937S, ISSN: 1078-0432.

Muraoka-Cook RS, Shin I, Yi JY, Easterly ME, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL. Activated type I TGFβ receptor kinase enhances survival of mammary epithelial cells and accelerates tumor progression. Oncogene. 2005; In press.

Reyzer ML, Caldwell RL, Dugger TC, Forbes JT, Ritter CA, Guix M, Arteaga CL, Caprioli RM. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res. 2004 Dec 12/15/2004; 64(24): 9093-100. PMID: 15604278, PII: 64/24/9093, DOI: 10.1158/0008-5472.CAN-04-2231, ISSN: 0008-5472.

Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res. 2004 Dec 12/15/2004; 64(24): 9002-11. PMID: 15604265, PII: 64/24/9002, DOI: 10.1158/0008-5472.CAN-04-2111, ISSN: 0008-5472.

Ritter CA, Bianco R, Dugger T, Forbes J, Qu S, Rinehart C, King W, Arteaga CL. Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model. Int J Clin Pharmacol Ther. 2004 Nov; 42(11): 642-3. PMID: 15598031, ISSN: 0946-1965.

Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J. Biol. Chem [print-electronic]. 2004 Jun 6/4/2004; 279(23): 24505-13. PMID: 15044465, PII: M400081200, DOI: 10.1074/jbc.M400081200, ISSN: 0021-9258.

Arteaga CL, Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. Cancer Cell. 2004 Jun; 5(6): 525-31. PMID: 15193255, PII: S1535610804001527, DOI: 10.1016/j.ccr.2004.05.028, ISSN: 1535-6108.

Arteaga CL, Truica CI. Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Semin. Oncol. 2004 Feb; 31(1 Suppl 3): 3-8. PMID: 15052538, PII: S0093775404000247, ISSN: 0093-7754.

Arteaga CL. Cdk inhibitor p27Kip1 and hormone dependence in breast cancer. Clin. Cancer Res. 2004 Jan 1/1/2004; 10(1 Pt 2): 368S-71S. PMID: 14734493, ISSN: 1078-0432.

Brown KA, Roberts RL, Arteaga CL, Law BK. Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein. Breast Cancer Res [print-electronic]. 2004; 6(2): R130-9. PMID: 14979923, PMCID: PMC400660, PII: bcr762, DOI: 10.1186/bcr762, ISSN: 1465-542X.

Brown, Kimberly, Roberts, Richard, Arteaga, Carlos, Law, Brian.. Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation or retinoblastoma tumor suppressor protein. Breast Cancer Res. 2004; 6(2): R130-R139.

Arteaga CL. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J. Clin. Oncol. 2003 Dec 12/1/2003; 21(23 Suppl): 289s-291s. PMID: 14645415, PII: JCO.2003.10.523, DOI: 10.1200/JCO.2003.10.523, ISSN: 0732-183X.

Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol. Cell. Biol. 2003 Dec; 23(23): 8691-703. PMID: 14612410, PMCID: PMC262670, ISSN: 0270-7306.

Arteaga CL. Inhibiting tyrosine kinases: successes and limitations. Cancer Biol. Ther. 2003 Jul; 2(4 Suppl 1): S79-83. PMID: 14508084, PII: 206, ISSN: 1538-4047.

Dumont N, Arteaga CL. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell. 2003 Jun; 3(6): 531-6. PMID: 12842082, PII: S1535610803001351, ISSN: 1535-6108.

Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin. Oncol. 2003 Jun; 30(3 Suppl 7): 3-14. PMID: 12840796, PII: S0093775403001854, ISSN: 0093-7754.

Matheny KE, Barbieri CE, Sniezek JC, Arteaga CL, Pietenpol JA. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. Laryngoscope. 2003 Jun; 113(6): 936-9. PMID: 12782800, DOI: 10.1097/00005537-200306000-00004, ISSN: 0023-852X.

Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003 May 5/8/2003; 22(18): 2812-22. PMID: 12743604, PII: 1206388, DOI: 10.1038/sj.onc.1206388, ISSN: 0950-9232.

Arteaga CL, Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin. Cancer Res. 2003 May; 9(5): 1579-89. PMID: 12738709, ISSN: 1078-0432.

Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp. Cell Res. 2003 Mar 3/10/2003; 284(1): 122-30. PMID: 12648471, PII: S0014482702001040, ISSN: 0014-4827.

Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. 2003 Feb; 30(1 Suppl 1): 3-11. PMID: 12644979, PII: S0093775402000295, DOI: 10.1053/sonc.2003.50027, ISSN: 0093-7754.

Dumont N, Arteaga CL. A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells. Biochem. Biophys. Res. Commun. 2003 Jan 1/31/2003; 301(1): 108-12. PMID: 12535648, PII: S0006291X02029777, ISSN: 0006-291X.

Dumont N, Bakin AV, Arteaga CL. Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J. Biol. Chem [print-electronic]. 2003 Jan 1/31/2003; 278(5): 3275-85. PMID: 12421823, PII: M204623200, DOI: 10.1074/jbc.M204623200, ISSN: 0021-9258.

Arteaga CL. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res [print-electronic]. 2003; 5(2): 96-100. PMID: 12631388, PMCID: PMC154152, ISSN: 1465-542X.

Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin. Cancer Res. 2003 Jan; 9(1 Pt 2): 511S-5S. PMID: 12538508, ISSN: 1078-0432.

Matheny, Keith E, Barbieri, Christopher E, Sniezek, Joseph C, Arteaga, Carlos L, Pietenpol, Jennifer, A.. Inhibition of edpidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. Laryngoscope. 2003; 113(6): 936-9.

Dumont N, Arteaga CL. The tumor microenvironment: a potential arbitrator of the tumor suppressive and promoting actions of TGFbeta. Differentiation. 2002 Dec; 70(9-10): 574-82. PMID: 12492498, PII: dif700910, ISSN: 0301-4681.

Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med [print-electronic]. 2002 Oct; 8(10): 1145-52. PMID: 12244301, PII: nm759, DOI: 10.1038/nm759, ISSN: 1078-8956.

Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 2002 Oct; 29(5 Suppl 14): 3-9. PMID: 12422308, DOI: 10.1053/sonc.2002.35642, ISSN: 0093-7754.

Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, Dikov MM, Nadaf SR, Arteaga CL, Carbone DP. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology. 2002 Oct; 123(4): 1191-204. PMID: 12360481, PII: S001650850200224X, ISSN: 0016-5085.

Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. P38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J. Cell. Sci. 2002 Aug 8/1/2002; 115(Pt 15): 3193-206. PMID: 12118074, ISSN: 0021-9533.

Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002 Jul 7/15/2002; 62(14): 4132-41. PMID: 12124352, ISSN: 0008-5472.

Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin. Oncol. 2002 Jun; 29(3 Suppl 11): 4-10. PMID: 12138392, PII: asonc02903l0004, ISSN: 0093-7754.

Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 2002 Jun; 109(12): 1551-9. PMID: 12070302, PMCID: PMC151012, DOI: 10.1172/JCI15234, ISSN: 0021-9738.

Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, Roebuck LR, Arteaga CL. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol. 2002 Apr; 22(7): 2204-19. PMID: 11884607, PMCID: PMC133673, ISSN: 0270-7306.

Arteaga CL, Khuri F, Krystal G, Sebti S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin. Oncol. 2002 Feb; 29(1 Suppl 4): 15-26. PMID: 11894010, PII: asonc02901e0015, ISSN: 0093-7754.

Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist. 2002; 7 Suppl 4: 31-9. PMID: 12202786, ISSN: 1083-7159.

Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001 Dec 12/15/2001; 61(24): 8887-95. PMID: 11751413, ISSN: 0008-5472.

Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin. Cancer Res. 2001 Dec; 7(12 Suppl): 4436s-4442s; discussion 4411s. PMID: 11916237, ISSN: 1078-0432.

Arteaga CL, Chinratanalab W, Carter MB. Inhibitors of HER2/neu (erbB-2) signal transduction. Semin. Oncol. 2001 Dec; 28(6 Suppl 18): 30-5. PMID: 11774203, PII: asonc02806p0030, ISSN: 0093-7754.

Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL. Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol. Biol. Cell. 2001 Nov; 12(11): 3328-39. PMID: 11694570, PMCID: PMC60258, ISSN: 1059-1524.

Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol. 2001 Nov; 13(6): 491-8. PMID: 11673690, ISSN: 1040-8746.

Busse D, Yakes FM, Lenferink AE, Arteaga CL. Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance. Semin. Oncol. 2001 Oct; 28(5 Suppl 16): 47-55. PMID: 11706396, PII: asonc02805n0047, ISSN: 0093-7754.

Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 2001 Sep 9/15/2001; 19(18 Suppl): 32S-40S. PMID: 11560969, ISSN: 0732-183X.

Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res. 2001 Sep 9/1/2001; 61(17): 6583-91. PMID: 11522658, ISSN: 0008-5472.

Muraoka RS, Lenferink AE, Simpson J, Brantley DM, Roebuck LR, Yakes FM, Arteaga CL. Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. J. Cell Biol. 2001 May 5/28/2001; 153(5): 917-32. PMID: 11381079, PMCID: PMC2174338, ISSN: 0021-9525.

Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell. 2001 Jan; 12(1): 27-36. PMID: 11160820, PMCID: PMC30565, ISSN: 1059-1524.

Busse D, Doughty RS, Arteaga CL. HER-2/neu (erbB-2) and the cell cycle. Semin. Oncol. 2000 Dec; 27(6 Suppl 11): 3-8; discussion 92. PMID: 11236025, ISSN: 0093-7754.

Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 2000 Nov 11/24/2000; 275(47): 36803-10. PMID: 10969078, PII: M005912200, DOI: 10.1074/jbc.M005912200, ISSN: 0021-9258.

Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000 Oct 10/15/2000; 60(20): 5887-94. PMID: 11059787, ISSN: 0008-5472.

Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc. Natl. Acad. Sci. U.S.A. 2000 Aug 8/15/2000; 97(17): 9609-14. PMID: 10931950, PMCID: PMC16912, PII: 160564197, DOI: 10.1073/pnas.160564197, ISSN: 0027-8424.

Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, Shawver LK, Arteaga CL. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J. Biol. Chem. 2000 Mar 3/10/2000; 275(10): 6987-95. PMID: 10702262, ISSN: 0021-9258.

Gobbi H, Arteaga CL, Jensen RA, Simpson JF, Dupont WD, Olson SJ, Schuyler PA, Plummer WD, Page DL. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology. 2000 Feb; 36(2): 168-77. PMID: 10672063, PII: hiso841, ISSN: 0309-0167.

Dumont N, Arteaga CL. Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Res [print-electronic]. 2000; 2(2): 125-32. PMID: 11250702, PMCID: PMC139434, ISSN: 1465-5411.

Gobbi H, Dupont WD, Simpson JF, Plummer WD, Schuyler PA, Olson SJ, Arteaga CL, Page DL. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J. Natl. Cancer Inst. 1999 Dec 12/15/1999; 91(24): 2096-101. PMID: 10601380, ISSN: 0027-8874.

Arteaga CL. Foundations of molecular therapies in breast carcinoma. J Mammary Gland Biol Neoplasia. 1999 Oct; 4(4): 333-5. PMID: 10705917, ISSN: 1083-3021.

Arteaga CL, Koli KM, Dugger TC, Clarke R. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J. Natl. Cancer Inst. 1999 Jan 1/6/1999; 91(1): 46-53. PMID: 9890169, ISSN: 0027-8874.

Ohmori T, Yang JL, Price JO, Arteaga CL. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp. Cell Res. 1998 Dec 12/15/1998; 245(2): 350-9. PMID: 9851876, PII: S0014-4827(98)94261-6, DOI: 10.1006/excr.1998.4261, ISSN: 0014-4827.

Ohmori T, Arteaga CL. Protein kinase C epsilon translocation and phosphorylation by cis-diamminedichloroplatinum(II) (CDDP): potential role in CDDP-mediated cytotoxicity. Cell Growth Differ. 1998 Apr; 9(4): 345-53. PMID: 9563854, ISSN: 1044-9523.

Arteaga CL, Ramsey TT, Shawver LK, Guyer CA. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J. Biol. Chem. 1997 Sep 9/12/1997; 272(37): 23247-54. PMID: 9287333, ISSN: 0021-9258.

Koli KM, Ramsey TT, Ko Y, Dugger TC, Brattain MG, Arteaga CL. Blockade of transforming growth factor-beta signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells. J. Biol. Chem. 1997 Mar 3/28/1997; 272(13): 8296-302. PMID: 9079651, ISSN: 0021-9258.

Dixit M, Yang JL, Poirier MC, Price JO, Andrews PA, Arteaga CL. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J. Natl. Cancer Inst. 1997 Mar 3/5/1997; 89(5): 365-73. PMID: 9060958, ISSN: 0027-8874.

Koli KM, Arteaga CL. Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells. Cancer Res. 1997 Mar 3/1/1997; 57(5): 970-7. PMID: 9041203, ISSN: 0008-5472.

Koli KM, Arteaga CL. Complex role of tumor cell transforming growth factor (TGF)-beta s on breast carcinoma progression. J Mammary Gland Biol Neoplasia. 1996 Oct; 1(4): 373-80. PMID: 10887511, ISSN: 1083-3021.

Arteaga CL, Moses HL. TGF-beta in mammary development and neoplasia. J Mammary Gland Biol Neoplasia. 1996 Oct; 1(4): 327-9. PMID: 10887506, ISSN: 1083-3021.

Holt JT, Arteaga CB, Robertson D, Moses HL. Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA. Hum. Gene Ther. 1996 Jul 7/10/1996; 7(11): 1367-80. PMID: 8818724, DOI: 10.1089/hum.1996.7.11-1367, ISSN: 1043-0342.

Arteaga CL, Holt JT. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res. 1996 Mar 3/1/1996; 56(5): 1098-103. PMID: 8640767, ISSN: 0008-5472.

Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA. Growth retardation and tumour inhibition by BRCA1. Nat. Genet. 1996 Mar; 12(3): 298-302. PMID: 8589721, DOI: 10.1038/ng0396-298, ISSN: 1061-4036.

Arteaga CL, Dugger TC, Hurd SD. The multifunctional role of transforming growth factor (TGF)-beta s on mammary epithelial cell biology. Breast Cancer Res. Treat. 1996; 38(1): 49-56. PMID: 8825122, ISSN: 0167-6806.

Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein. Cancer Res. 1994 Sep 9/1/1994; 54(17): 4703-9. PMID: 8062268, ISSN: 0008-5472.

Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ. P185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. 1994 Jul 7/15/1994; 54(14): 3758-65. PMID: 7913407, ISSN: 0008-5472.

Moses HL, Arteaga CL, Alexandrow MG, Dagnino L, Kawabata M, Pierce DF, Serra R. TGF beta regulation of cell proliferation. Int. Symp. Princess Takamatsu Cancer Res. Fund. 1994; 24: 250-63. PMID: 8983080.

Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J. Clin. Invest. 1993 Dec; 92(6): 2569-76. PMID: 7504687, PMCID: PMC288452, DOI: 10.1172/JCI116871, ISSN: 0021-9738.

Hernández-Sotomayor SM, Arteaga CL, Soler C, Carpenter G. Epidermal growth factor stimulates substrate-selective protein-tyrosine-phosphatase activity. Proc. Natl. Acad. Sci. U.S.A. 1993 Aug 8/15/1993; 90(16): 7691-5. PMID: 8102801, PMCID: PMC47208, ISSN: 0027-8424.

Halter SA, Winnier AR, Arteaga CL. Pretreatment with vitamin A inhibits transforming growth factor alpha stimulation of human mammary carcinoma cells. J. Cell. Physiol. 1993 Jul; 156(1): 80-7. PMID: 7686167, DOI: 10.1002/jcp.1041560112, ISSN: 0021-9541.

Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ. 1993 Mar; 4(3): 193-201. PMID: 8466857, ISSN: 1044-9523.

Arteaga CL, Dugger TC, Winnier AR, Forbes JT. Evidence for a positive role of transforming growth factor-beta in human breast cancer cell tumorigenesis. J. Cell. Biochem. Suppl. 1993; 17G: 187-93. PMID: 8007696, ISSN: 0733-1959.

Romano M, Polk WH, Awad JA, Arteaga CL, Nanney LB, Wargovich MJ, Kraus ER, Boland CR, Coffey RJ. Transforming growth factor alpha protection against drug-induced injury to the rat gastric mucosa in vivo. J. Clin. Invest. 1992 Dec; 90(6): 2409-21. PMID: 1281834, PMCID: PMC443397, DOI: 10.1172/JCI116132, ISSN: 0021-9738.

Arteaga CL. Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res. Treat. 1992; 22(1): 101-6. PMID: 1421419, ISSN: 0167-6806.

Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc. Natl. Acad. Sci. U.S.A. 1991 Dec 12/1/1991; 88(23): 10435-9. PMID: 1683701, PMCID: PMC52943, ISSN: 0027-8424.

Arteaga CL, Coffey RJ, Dugger TC, McCutchen CM, Moses HL, Lyons RM. Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta. Cell Growth Differ. 1990 Aug; 1(8): 367-74. PMID: 2177634, ISSN: 1044-9523.

Available Postdoctoral Position Details
Posted: 4/1/2014
The laboratory of Carlos L. Arteaga, MD in the Breast Cancer Program of the Vanderbilt-Ingram Comprehensive Cancer Center is recruiting post-doctoral research fellows

Projects include:

Discovery of mechanisms of resistance to antiestrogen therapy in breast cancer; Development of transgenic mouse models of basal-like breast cancer; Genomic profiling of drug-resistant ER+ and triple negative breast cancer; Discovery of rational combinations of targeted therapies in breast cancer (focus on PI3K/AKT, ERBB receptors, TGF???, ER???, CDK4)


Methods include gain-of-function kinase screens, next gen sequencing, RNAseq, mass spectrometry, RNAi screens, functional small animal imaging, molecular profiling and discovery using primary tumors from patients in clinical trials with targeted therapies, and studies with cell lines and xenografts using conditional shRNAs and targeted therapies in clinical development in vitro and in vivo


Recent relevant publications that apply to these topics include:
Miller TW, Fox EM, Balko JM, Ghazoui A, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, S??nchez V, Maira S-M, Manning HC, Gonz??lez-Angulo AM, Mills GB, Higham C, Ye F, Miller WR, Shyr Y, Arteaga CL. ER???-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discovery 1:338-51, 2011

Chakrabarty A, S??nchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor action of phosphatidylinositol-3 kinase pathway inhibitors. Proc. Natl. Acad. Sci. USA 109:2718-23, 2012

Arteaga CL, Baselga J. Impact of Genomics in Personalized Cancer Medicine. Clin. Cancer Res. 18:612-8, 2012

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonz??lez-Angulo AM, Mills GB, Pinto JA, Gomez HL, Arteaga CL. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature Med. 18:1052-9, 2012

Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, S??nchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc. Natl. Acad. Sci. USA 109:221-6, 2012

Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, S??nchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression or signaling. Cancer Res. 73:4075-85, 2013

Bhola N, Balko JM, Dugger TC, Kuba MG, Stanford J, Cook RS, Arteaga CL. TGF?? inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123:1348-58, 2013

Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL. Autocrine IGF/insulin receptor axis compensates for inhibition of AKT in ER positive breast cancer cells with acquired resistance to estrogen deprivation. Breast Cancer Res. 2013 Jul 11; 15(4):R55 [Epub ahead of print]

Balko JM, Stricker TP, Arteaga CL. The genomic map of breast cancer: Which roads lead to better targeted therapies? Breast Cancer Res. 2013 Jul 31;15(4):209 [Epub ahead of print]

Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, DeFazio-Eli L, Arteaga CL. Combination of antibody that blocks ligand-independent HER3 dimerization and a p110??? inhibitor potently block PI3K signaling and growth of HER2-overexpressing breast cancers. Cancer Res. 73:6013-23, 2013

Hanker AB, Pfefferle A, Balko JM, Kuba MG, Young CD, S??nchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc. Natl. Acad. Sci. USA 110:14372-7, 2013

Balko JM, Schwarz LJ, Bhola N, Kurupi R, Owens P, Miller TW, G??mez H, Cook RS, Arteaga CL. Activation of MAPK pathways via DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 73:5346-58, 2013

Balko JM, Giltnane JM, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, S??nchez V, Pinto JA, Doimi F, G??mez H, Goga A, Lehmann B, Bauer J, Pietenpol JA, Stephens PA, Cronin M, Miller VA, Yelensky R, Wang K, Palmer G, Arteaga CL. Molecular profiling of drug-resistant tumor cells remaining in the breast after neoadjuvant chemotherapy of triple-negative breast cancers identifies actionable therapeutic targets. Cancer Discov. 4:232-245, 2014

Mayer IA, Abramson VG, Isakoff SJ, Forero-Torres A, Balko JM, Kuba MG, Sanders ME, Yap J, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin. Oncol. (In press), 2014

Arteaga CL, Engelman JA. ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (In press), 2014

Interested applicants should send updated CV and list of references to carlos.arteaga@vanderbilt.edu

Carlos L. Arteaga, MD
Professor of Medicine and Cancer Biology
Associate Director for Clinical Research
Director Center for Cancer Targeted Therapies
Director Breast Cancer Program
Vanderbilt-Ingram Cancer Center
Vanderbilt University

Div. Hematology-Oncology, VUMC
2220 Pierce Avenue, 777 PRB
Nashville, TN 37232-6307

Assistant:
Heather Burgess
heather.burgess@vanderbilt.edu

Tel. 615 936 3524
Fax 615 936 1790